Time filter

Source Type

Movahedi M.,Shahid Beheshti University of Medical Sciences | Movahedi M.,Tehran University of Medical Sciences | Haghighat S.,Tehran University of Medical Sciences | Haghighat S.,Iranian Center for Breast Cancer | And 5 more authors.
Iranian Red Crescent Medical Journal | Year: 2012

Background: Breast cancer is the most common cancer among women worldwide. Based on the latest Iranian national cancer department report, the total number of women registered with breast cancer was 6976 cases during 2007. Five year survival is one of the indicators used for evaluation of the quality for care to different types of malignancies including breast cancer. Objectives: The aim of this study was to estimate survival rate of breast cancer in 6147 Iranian patients at a national level in different geographic regions. Materials and Methods: 6147 cases of breast cancer, which had telephone number and were diagnosed between 2001-2006, were called to obtain information about their life status. Survival estimates were calculated using the Kaplan-Meier method, and the survival probability was calculated for the overall cohort and in different categories of gender, age and pathologic type of tumor. Hazard ratios (HR) according to demographic and risk variables were calculated by Cox's proportional hazard model. Results: The overall 5-year survival rate was 71.0%. The mean survival time was different between men and women, which was statistically significant. The number of men involved with breast cancer was 172 (2.8%) of all cases. The 5-year survival rate for patients in age group 41-50 years was significantly higher than other age groups (P = 0.001). The likelihood of death was higher in patients with 61 years old or more years rather than those below forty years old (HR = 1.31; 95% CI: 1.12-1.55). Conclusions: The findings of this study might help Iranian health managers: 1) to be more conscious about geographical and regional determinants which will affect overall survival rate. 2) To carry preventive activities such as public education particularly in Iranian men. 3) To think about screening and early detection of breast cancer. Source

Salimi M.,Tarbiat Modares University | Mozdarani H.,Tarbiat Modares University | Majidzadeh-A K.,Iranian Center for Breast Cancer
Asian Pacific Journal of Cancer Prevention | Year: 2012

Considerable attention has been given to the accuracy of HER-2 testing and the correlation between the results of different testing methods. This interest reflects the growing importance of HER-2 status in the management of patients with breast cancer. In this study the detection of HER-2 gene and centromere 17 status was evaluated using dual-colour primed in situ labelling (PRINS) in comparison with fluorescence in situ hybridization (FISH). These two methods were evaluated on a series of 27 formalin fixed paraffin embedded breast carcinoma tumours, previously tested for protein overexpression by HercepTest (grouped into Hercep 1+/0, 2+ and 3+). HER-2 gene amplification (ratio≥2.2) by PRINS was found in 3:3, 6:21 and 0:3 in IHC 3+, 2+ and 1+/0 cases, respectively. Comparing FISH and IHC (immunohistochemistry), showed the same results as for PRINS and IHC. Chromosome 17 aneusomy was found in 10 of 21 IHC 2+ cases (47.6%), of which 1 (10%) showed hypodisomy (chromosome 17 copy number per cell≤1.75), 7 (70%) showed low polysomy (chromosome 17 copy number per cell=2.26-3.75) and 2 (20%) showed high polysomy (chromosome 17 copy number per cell ≥3.76). The overall concordance of detection of HER-2 gene amplification by FISH and PRINS was 100% (27:27). Furthermore, both the level of HER-2 amplification and copy number of CEN17 analysis results correlated well between the two methods. In conclusion, PRINS is a reliable, reproducible technique and in our opinion can be used as an additional test to determine HER-2 status in breast tumours. Source

Moniri Javadhesari S.,Islamic Azad University at Bonab | Gharechahi J.,Iran National Institute of Genetic Engineering and Biotechnology | Gharechahi J.,Iranian Center for Breast Cancer | Hosseinpour Feizi M.A.,University of Tabriz | And 2 more authors.
Genetic Testing and Molecular Biomarkers | Year: 2013

Survivin, which is a novel member of the inhibitor of apoptosis family proteins, is known to play an important role in the regulation of cell cycle and apoptosis. Differential expression of survivin in tumor tissues introduces it as a new candidate molecular marker for cancer. Here we investigated the expression of survivin and its splice variants in breast tumors, as well as normal adjacent tissues obtained from the same patients. Thirty five tumors and 17 normal adjacent tissues from women diagnosed with breast cancer were explored in this study. Differential expression of different survivin splice variants was detected and semiquantitatively analyzed using reverse transcription- polymerase chain reaction. Results showed that survivin and its splice variants were differentially expressed in tumor specimens compared with normal adjacent tissues. The expression of survivin-3B and survivin-3α was specifically detected in tumor tissues compared with normal adjacent ones (53% in tumor tissues compared to 5% in normal adjacent for survivin-3B and 65% in tumor tissues and 0.0% in normal adjacent tissues for survivin-3α). Statistical analysis showed that survivin and survivin-ΔEx3 were upregulated in benign (90%, p<0.034) and malignant (76%, p<0.042) tumors, respectively. On the other hand, our results showed that survivin-2α (100% of the cases) was the dominant expressed variant of survivin in breast cancer. The data presented here showed that survivin splice variants were differentially expressed in benign and malignant breast cancer tissues, suggesting their potential role in breast cancer development. Differential expression of survivin-2α and survivin-3α splice variants highlights their usefulness as new candidate markers for breast cancer diagnosis and prognosis. © Copyright 2013, Mary Ann Liebert, Inc. 2013. Source

Sajadian A.,Iranian Center for Breast Cancer | Montazeri A.,Iranian Institute for Health science Research
Iranian Journal of Epidemiology | Year: 2011

Background & Objectives: The experience of patients with breast cancer may vary in different cultures. The aim of this qualitative study was to explore the experiences of women with breast cancer in Iran. Methods: Fifty one participants were recruited from a university-affiliated breast clinic in Tehran. In-depth interviews each lasting approximately one hour per participant were scheduled and conducted in a private room. The interviews intended to motivate the participants to reflect on their life experiences since the cancer diagnosis. The interviews were tape-recorded and were transcribed to elucidate the major themes encountered in the interviews. Results: The mean age of patients was 48.8 years (SD = 10.5), 44 were married, one was single, and six were widowed or divorced. Forty-eight participants underwent radical mastectomy and 13 patients received breast-conserving surgery. Thirty-five (69%) patients received chemotherapy. Overall eight major themes emerged from the analysis. These were: importance of God and spiritual beliefs, importance of family support especially husbands and children during the diagnosis and treatment, difficult times during receiving mammography results, experiencing an ambiguous condition while losing their breasts, fear of recurrence, concerns about children, and chemotherapy as the worst experience during the course of treatment. Conclusion: The study results suggest that chemotherapy is the worst experience for women with breast cancer. This needs to be considered by oncologists in planning medical care for cancer patients. In addition it seems that patients' spiritual beliefs might be considered as an extra resource to help patients to overcome their problems. Source

Nasrinossadat A.,Iranian Center for Breast Cancer | Ladan F.,Iranian Center for Breast Cancer | Fereshte E.,Tehran University of Medical Sciences | Asieh O.,Iranian Center for Breast Cancer | And 3 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2011

Introduction: The widespread use of improved mammographic techniques has led to increased detection of nonpalpable breast masses. Preoperative localization is important for reducing false negative results and decreasing the size of tissue resection needed and the resulting breast deformity. We used ultrasound guided methylen blue injection in the mass for localization of breast masses that were clinically nonpalpable but detectable by ultrasound. Materials and methods: 57 masses from 51 patients were marked 20 to 180 minutes before surgery with 0.4-0.7 cc methylene blue and resection was done in operating room under local or general anesthesia. success of radiologist for localization and success of surgeon for complete resection and pathology results were reviwed and fallow up ultrasound was done 3-5 month after surgery for patients whom pathology report was non specific (such as FCC) to confirm complete resection. Results: 57 masses were excised successfully by the surgeon, localization was successful in all patients but injection in the mass was not feasible in 4 patients and dye was injected on the surface of the mass and led to successful excision .Only one mass was not found at surgery because dye washed out before surgery, and the mass was resected by use of intra operative ultrasound. 5.3% patients reported the procedure was painful and 28% reported tolerable pain during injection and 66.7 % of patients said that the injection was painless or with minimal discomfort. Allergic reaction was not seen in any patient and no interference was reported by the pathologist in slide preparation or diagnoses and IHC study. Conclusion: Marking with blue dye injection is a safe and low cost method for localization of non palpable breast lesions that are detectable by Ultrasound. In one patient failure to find the mass was because of location of the mass that was in axillary tail of breast and time of surgery that was 100 minutes after injection that led to absorption of blue dye before surgery and it is advised to do surgery as soon as possible after blue dye injection especially in peripheral and deeply located masses. Source

Discover hidden collaborations